ERBB2 and breast cancer: These genetic alterations compare to those previously reported for HR+/HER2 + ABC using the MSK-IMPACT assay in 109 patients, reflecting high consistency of the population’s genetic profile and emphasizing the reliability of these genetic alterations as significant drivers of ER+/HER2 + BC [46].